Tatalaksana terkini pada miastenia gravis

Lydia Susanti✉
DOI: https://doi.org/10.25077/mka.v45.i4.p564-574.2022

Abstract

Myasthenia gravis (MG) is a disorder of the neuromuscular junction that causes fluctuating muscle weakness. The etiology of this disease is due to the presence of antibodies that attack acetylcholine receptors on the postsynaptic membrane (autoimmune). Myasthenia gravis is a chronic disease and most MG patients fall into Generalized Myasthenia Gravis (gMG) within 2 years of onset. Myasthenic crisis is a serious condition and requires high-cost management. Therefore, disease management continues to be updated to reduce mortality and mortality, as well as improve quality of life. This article discusses the latest 

myasthenia gravis; guidelines 2020 ; immunosuppressants; plasmaparesis; ivig

Keywords

myasthenia gravis; guidelines 2020 ; immunosuppressants; plasmaparesis; ivig

Full Text:

PDF

References

Gilhus NE, Verschuuren JJ. Myasthenia Gravis: Subgroup Classification And Therapeutic Strategies. Lancet Neurol. 2015;10: 1023-36.

Grob D, et al. Lifetime Course of Myasthenia Gravis. Muscle Nerve. 2008;37(2):141-9.

Gilhus NE, et al. Autoimmune Myasthenia Gravis. Expert Review of Neurotherapeutics. 2009;9(3):351-8.

Carr AS, et al. A Systematic Review of Population Based Epidemiological Studies in Myasthenia Gravis. BMC Neurol. 2010;10:46.

Deenen JC, et al. Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. J Neuromuscul Dis. 2015;2(1):73-85.

Howard JF, et al. Safety and Efficacy of Eculizumab in Antiacetylcholine Receptor Antibody Positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study. Lancet Neurol. 2017;16(12):976-986.

Engel-Nitz NM, et al. Buerden of Illness in Patients With Treatent Refractory Myasthenia Gravis. Muscle Nerve. 2018. Doi:10.1002/mus.26114.

Barnett C, et al. A Conceptual Framework for Evaluating Impairments in Myasthenia Gravis. PLoS ONE. 2014;9(5):e98089.

Suh J, et al. Clinical Characteristics od Refractory Myasthenia Gravis Patients. Yale J Biol Med. 2013;86(2):255-260.

Blum S, et al. Clinical Features and Impact of Myasthenia Gravis Disease in Australian Patients. J Clin Neurosci. 2015;22(7):1164-9.

Frost A, et al. Labour Market Participation and Sick Leave Among Patients Diagnosed with Myasthenia Gravis in Denmark 1997-2011: A Danish Nationwide Cohort Study. BMC Neurol. 2016;16(1): 224.

Li Y, et al. Myasthenia Gravis: Newer Therapies Offer Sustained Improvement. Cleve Clin J Med. 2013;80(11):711-21.

Tortora GJ, Derrickson B. Muscular Tissue. In: Principles of Anatomy and Physiology. 14th ed. Hoboken, NJ: John Wiley and Sons Inc. 2014:291.

Gilhus NE, et al. Myasthenia Gravis-Autoantibody Characteristics and Their Implications for Therapy. Nat rev Neurol. 2016;12(5):259-68.

Huijbers MG, et al. Pathogenic Immune Meschanism at the Neuromuscular Synapse: The Role of Specific Antibody-Binding Epitopes in Myasthenia Gravis. J Intern Med. 2014;275(1):12-26.

Conti-Fine BM, et al. Myasthenia Gravis: Past, Present and Future. J Clin Invest. 2006;116(11):2843-54.

Juel VC, Massey JM. Myasthenia Gravis. Orphanet J Rare Dis. 2007;2:44.

Gwathmey KG, Burns TM. Myasthenia Gravis. Semin Neurol. 2015;35(4):327-29.

Pasnoor M, et al. Diagnosis of Myasthenia Gravis. Neurol Clin. 2018;36(2):261-274.

Barnett C, et al. Myasthenia Gravis Impairment Index: Responsiveness, meaningful Change, and Relative Efficiency. Neurology. 2017;89(23):2357-2364.

Abraham A, et al. The Utility of a Single Simple Question in the Evaluation of Patients with Myasthenia Gravis. Muscle Nerve. 2018;57(2):240-244.

Mendoza M, et al. Patient-Acceptable Symptom States in Myasthenia Gravis. Neurology. 2020;95(12):e1617-e1628.

Sanders DB, et al. International Consensus Guidance for Management of Myasthenia Gravis: Executive Summary. Neurology. 2016;87(4):419-25.

Narayanaswami, et al. Intenational Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122.

Sanders DB, et al. Clinical Aspects of MuSK Antibody Positive Seronegative MG. Neuorlogy. 2003;60(12):1978-80.

Huda S, et al. IgG-Specific Cell-Based Assay Detects Potentially Pathogenis MuSK-Abs in Seronegative MG. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e357.

Romi F, et al. Seronegative Myasthenia Gravis: Disease Severity and Prognosis. Eur J Neurol. 2005;12(6):413-8.

Alcantara M, et al. Chronic Immunoglobulin Maintenance Therapy in Myasthenia Gravis. Eur J Neurol. 2021;28(2):639-646.

Nowak RJ, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology. 2021;98(4):e376-89.

Beecher G, et al. Rituximab in Refractory Myasthenia Gravis: Extended Prospective Study Results. Muscle Nerve. 2018;58(3):452-455.

Anderson D, et al. Rituximab in Refractory Myasthenia Gravis: A Prospective, Open-Label Study With Long Term Folloe-up. Ann Clin Transl Neurol. 2016;3(7):552-5.

Topakian R, et al. High Efficacy of Rituximab for Myasthenia Gravis: A Comprehensive Nationwide Study in Austria. J Neurol.2019; 266:699-706.

Afanasiev V, et al. Resistant Myasthenia Gravis and Rituximab: A Monocentric Retrospective Study of 28 Patients. Neuromuscul Disord. 2017;27(3):251-258.

Hehir MK, et al. Rituximab as Treatment for Anti-MuSK Myasthenia Gravis: Multicenter Blinded Prospective Review. Neurology. 2017;89(10):1069-1077.

Paul F, et al. Infusion-related Reactions to Rituximab: Frequency, Mechanisms and Predictors. Expert Rev Clin Immunol. 2019;15(4):383-389.

Damato V, et al. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. JAMA Neurol. 2016;73(11):1342-1348.

Tavakolpour S, et al. A Comprehensive Review of Rituximab Therapy in Rheumatoid Arthritis Patients. Clin Rheumatol. 2019;38(11):2977-2994.

Rother RP, et al. Discovery and Development of the Complement Inhibitor Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Nat Biotechnol. 2007;25(11): 1256-64.

Dunkelberger JR, et al. Complement and its Role in Innate and Adaptive Immune Responses. Cell Res. 2010;20(1):34-50.

Mantegazza R, et al. Post-intervention Status in Patients with Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN ang Its Open Label Extension. Neurology. 2021;96(4):e610-e618.

Howard JF, et al. Safety, Efficacy, and Tolerability of Efgartigimod in Patients with Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-controlled, Phase 3 Trial. Lancet Neurol. 2021;20(7):526-536.

Farmakidis C, et al. Treatment of Myasthenia Gravis. Neurol Clin. 2018;36(2):311-337.

Datta S, et al. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series. J Neuromuscul Dis. 2020;7:269-277.

Menon D, et al. Novel Treatments in Myasthenia Gravis. Front Neurol. 2020;11:538.

Howard JF, et al. Clinical Effects of the Self-Administrated Subcutaneous Complement Inhibitor Zilucoplam in Patients with Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020;77(5):582-592.

Bril V, et al. Efficacy and Safety of Rozanolixizumab in Moderate to severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. Neurology. 2021;96(6):e853-e865,

Schneider-Gold C, et al. Advances and Challenges in the Treatment of Myasthenia Gravis. Ther Adv Neurol Disord. 2021;14:17562864211065406.



Bookmark and Share
-->